期刊文献+

脓毒症患者抗菌药物的个体化治疗 被引量:9

Individualized antimicrobial therapy for septic patients
下载PDF
导出
摘要 脓毒症定义为针对感染的宿主反应失调引起的致命性器官功能障碍,其院内病死率超过10%,而患者出现脓毒性休克时,院内病死率将超过40%。脓毒症患者常遭受耐药菌感染,同时具有器官功能障碍,抗菌药物的药动学(PK)和药效学(PD)发生了显著变化,从而影响抗菌药物的疗效,给药方案应根据其PK/PD特点实施个体化治疗。
作者 李文雄
出处 《中国感染与化疗杂志》 CAS CSCD 北大核心 2016年第4期515-520,共6页 Chinese Journal of Infection and Chemotherapy
基金 北京市卫生系统高层次卫生技术人才学科骨干基金(2011-3-016)
  • 相关文献

参考文献33

  • 1ANGUS DC, LINDE-ZWIRBLE WT, LIDICKER J, et al. Epidemiology of severe sepsis in the United States : analysis of incidence, outcome, and associated costs of care[J]. Crit Care Med, 2001, 29 ( 7 ) : 1303-1310.
  • 2ROBERTS JA, PAUL SK, AKOVA M, et al. DALI : defining antibiotic levels in intensive care unit patients : are current 13-1actam antibiotic doses sufficient for critically ill patients ? [J]. Clin Infect Dis, 2014, 58 ( 8 ) : 1072-1083.
  • 3ROBERTS JA, ABDUL-AZIZ MH, LIPMAN J, et al. Individualised antibiotic dosing for patients who are criticallyill : challenges and potential solutions[J]. Lancet Infect Dis, 2014, 14 (6) : 498-509.
  • 4ROBERTS JA, LIPMAN J. Pharmacokinetic issues for antibiotics in the critically ill patient[J]. Crit Care Med, 2009, 37 (3) : 840-851.
  • 5FERRIOLS-LISART R, ALOS-ALMIIqANA M. Effectiveness and safety of once-daily aminoglycosides : a meta-analysis[J]. Am JHealth Syst Pharm, 1996, 53 (10): 1141-1150.
  • 6NICOLAU DP, FREEMAN CD, BELLIVEAU PP, et al. Experience with a once-daily aminoglycoside program administered to 2, 184 adult patients[J]. Antimicrob Agents Chemother, 1995, 39 ( 3 ) : 650-655.
  • 7FORREST A, NIX DE, BALLOW CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients[J]. Antimicrob Agents Chemother, 1993, 37 ( 5 ) : 1073-1081.
  • 8THOMAS JK, FORREST A, BHAVNANI SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy[J]. Antimicrob Agents Chemother, 1998, 42 ( 3 ) : 521-527.
  • 9SHORR AF, KHASHAB MM, XIANG JX, et al. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients[J]. Respir Med, 2006, 100 ( 12 ) : 2129-2136.
  • 10BOSELLI E, BREILH D, RIMMELE T, et al. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia[J]. Crit Care Med, 2005, 33 ( 1 ) : 104-109.

同被引文献66

引证文献9

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部